Gleptosil vet.
Active substance
ATC code
Species
Neonatal pigs
Indications
Neonatal pigs:
For the prevention and treatment of iron deficiency anaemia.
Dose to be administered and administration route
Use only automatic syringe equipment
Swab the septum before use. The product is administered as a single 1 mL (200 mg iron) dose by deep intramuscular injection into the hind limb midway between the stifle joint and the base of the tail. Injections should be administered as follows:
FOR THE PREVENTION OF IRON DEFICIENCY ANAEMIA: not later than the third day of life. FOR THE TREATMENT OF IRON DEFICIENCY ANAEMIA: at the onset of clinical anaemia, normally within the first three weeks of life.
For 100 & 250 ml plastic vials: as the vial cannot be broached more than 20 times, use of automatic syringe equipment is recommended.
For 100 ml collapsible vial: as the vial cannot be broached more than 4 times, the use of automatic syringe equipment is recommended.
Adverse reactions
There are normally no undesirable side effects associated with the use of the product. Its use does not result in permanent staining of the injected muscle tissue.
Dispensing
POM-VPS - Prescription Only Medicine – Veterinarian, Pharmacist, SQPSUMMARY OF PRODUCTS CHARACTERISTICS
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Gleptosil 200mg/ml solution for injection
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Substance:
Iron 200 mg/ml
(as gleptoferron complex). 498 mg/ml)
Excipients:
Phenol 5 mg/ml
For the full list of excipients see
Section 6.1
3. PHARMACEUTICAL FORM
Solution for injection.
A dark brown, slightly viscous, sterile, colloidal, aqueous solution
4. CLINICAL PARTICULARS
4.1 Target species
Neonatal pigs
4.2 Indications for use, specifying the target species
Neonatal pigs:
For the prevention and treatment of iron deficiency anaemia.
4.3 Contraindications
None
4.4 Special warnings for each target species
None
4.5 Special precautions for use
i) Special precautions for use in animals
Normal aseptic injection techniques should be practised. ii) Special precautions for the person administering the veterinary
medicinal product to animals
Care should be taken to avoid accidental self injection. In the event of accidental self injection seek medical advice. Wash hands after use.
iii) Other precautions
The sachet should not be opened until the product is required for use.
Avoid the introduction of contamination during use.
4.6 Adverse reactions (frequency and seriousness)
There are normally no undesirable side effects associated with the use of the product. Its use does not result in permanent staining of the injected muscle tissue.
4.7 Use during pregnancy, lactation or lay
Not applicable
4.8 Interaction with other medicinal products and other forms of interaction
There are no known interactions between the product and other medicaments. There are no known other forms of interaction. Do not mix with other products prior to administration.
4.9 Amount to be administered and administration route
Use only automatic syringe equipment
Swab the septum before use. The product is administered as a single 1 mL (200 mg iron) dose by deep intramuscular injection into the hind limb midway between the stifle joint and the base of the tail. Injections should be administered as follows:
FOR THE PREVENTION OF IRON DEFICIENCY ANAEMIA: not later than the third day of life. FOR THE TREATMENT OF IRON DEFICIENCY ANAEMIA: at the onset of clinical anaemia, normally within the first three weeks of life.
For 100 & 250 ml plastic vials: as the vial cannot be broached more than 20 times, use of automatic syringe equipment is recommended.
For 100 ml collapsible vial: as the vial cannot be broached more than 4
times, the use of automatic syringe equipment is recommended.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
Overdosage with the product is unlikely to result in signs of intoxication.
4.11 Withdrawal period
MEAT AND OFFAL: ZERO DAYS.
5. PHARMACOLOGICAL PROPERTIES
Pharmacotherapeutic group: Antianaemic preparations, Iron
preparations, Iron trivalent, parenteral preparations
ATCVet Code: QBO3AC
5.1 Pharmacodynamic properties
Injectable iron-carbohydrate complexes are established haematinic agents in veterinary medicine. Following intramuscular injection, the complex is absorbed and metabolised to release the iron for utilisation and/or storage in accordance with the nutritional status of the animal. In iron deficient states, the iron is utilised for the synthesis of haemoglobin and other iron-containing molecules. Excess iron is stored principally in the liver.
5.2 Pharmacokinetic properties
Absorption of the product has been shown to be rapid. Over 95% of the administered iron (1mL/200 mg iron administered at three days of age) was absorbed by 24 hours after injection. Use of the product does not result in permanent staining of the injected muscle tissue.
5.3 Environmental properties
Not applicable
6. PHARMACEUTICAL PARTICULARS
6.1. List of excipients
Phenol
Sodium chloride
Water for injections
6.2. Major incompatibilities
None known
6.3. Shelf life
Shelf life of the veterinary medicinal product as packaged for sale in 100 ml collapsible vial: 2 years.
Shelf life after opening the immediate packaging: 28 days Shelf-life of the veterinary medicinal product as packaged for sale in 100 & 250 ml multilayer plastic vials: 3 years.
6.4. Special precautions for storage
Do not store above 25°C. Protect from light.
6.5. Nature and composition of immediate packaging
100 mL clear colourless low-density polyethylene collapsible bottles with grey chlorbutyl rubber bung with aluminium overseal.
6.6. Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products, if appropriate
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
7. MARKETING AUTHORISATION HOLDER
Ceva Animal Health Ltd
Explorer House
Mercury Park
Wycombe Lane
Wooburn Green
High Wycombe
Buckinghamshire
HP10 0HH
United Kingdom
8. MARKETING AUTHORISATION NUMBER
Vm 15052/4079
9. DATE OF FIRST AUTHORISATION
30 August 1995
10. DATE OF REVISION OF THE TEXT
October 2022
Approved: 06 October 2022

Art. Nr. | 15052/4079 |
---|---|
EAN | 3411113021139 |